Transplant Evaluation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transplant evaluation is a comprehensive, multi-disciplinary assessment carried out by a specialised transplant centre to determine whether a patient is medically, psychologically, and socially suitable to receive a solid-organ transplant. It is the mandatory gateway before a patient can be placed on a national or regional transplant waiting list.

Organs most commonly evaluated for transplantation include the kidney (the most frequently transplanted organ worldwide), liver, heart, lungs, pancreas, and — more rarely — the small intestine or combined multi-organ grafts. Evaluation protocols are organ-specific but share a common framework of medical suitability, infectious disease screening, cancer surveillance, cardiovascular risk assessment, and psychosocial readiness.

The evaluation process typically spans two to eight weeks and involves visits with numerous specialists. The result is a formal recommendation from the transplant selection committee: approved for listing, conditionally deferred (pending optimisation of a correctable problem), or declined (absolute medical or psychosocial contraindication). Patients who are deferred can usually be re-evaluated once the underlying issue is resolved.

Understanding the evaluation process helps patients prepare, reduces anxiety, and enables them to take an active role in gathering records, optimising their health, and building the support network required for post-transplant success.

Transplant evaluation is initiated when a patient's organ function has declined to a level where transplantation offers the best chance of survival or meaningful quality-of-life improvement. Common conditions by organ type include:

• Kidney: End-stage renal disease (ESRD) from diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy, polycystic kidney disease, lupus nephritis, or focal segmental glomerulosclerosis. Patients are typically referred when estimated GFR falls below 20 mL/min/1.73 m².
• Liver: Decompensated cirrhosis (MELD score ≥15) from alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), chronic hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, and hepatocellular carcinoma within Milan criteria.
• Heart: Advanced heart failure (NYHA class III–IV) refractory to optimal medical therapy, ischaemic or dilated cardiomyopathy, cardiac sarcoidosis, restrictive cardiomyopathy, and certain congenital heart diseases in adults.
• Lung: COPD/emphysema, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, lymphangioleiomyomatosis, and bronchiectasis.
• Pancreas: Type 1 diabetes mellitus with hypoglycaemia unawareness or labile glycaemia, often combined with a kidney transplant (SPK — simultaneous pancreas-kidney).

Timing of referral is critical. Early referral — before the patient becomes too ill to tolerate transplantation — is associated with significantly better outcomes. Nephrologists and hepatologists are encouraged by international guidelines to refer patients before they reach the dialysis or decompensation stage.

Eligibility assessment is individualised, but general criteria apply across organ types. Inclusion criteria typically include end-stage or advanced organ failure with no adequate medical or surgical alternative, acceptable operative risk, absence of active untreated infection or malignancy, psychosocial stability, and commitment to lifelong immunosuppression and follow-up.

Absolute contraindications — reasons a transplant cannot be offered — typically include:

• Active or recently treated malignancy outside defined cure criteria (varies by cancer type and centre)
• Uncontrolled systemic infection including active tuberculosis, HIV without adequate viral suppression, or untreated fungal infection
• Severe irreversible disease in another organ system (e.g., advanced COPD in a kidney candidate) that would preclude survival benefit
• Active substance use disorder (alcohol, illicit drugs) without a documented period of sobriety and treatment engagement
• Non-adherence with previous medical therapy without remediable cause
• Refractory pulmonary hypertension (for renal or hepatic transplants) beyond accepted thresholds

Relative contraindications are individually assessed and may include morbid obesity (BMI >40), significant frailty, advanced age, limited social support, and certain neurological or psychiatric conditions. Many of these can be addressed pre-transplant to move a patient from deferred to approved status. A dedicated social worker and transplant coordinator guide patients through these correctable barriers.

The evaluation process is structured, thorough, and coordinated by a transplant coordinator who serves as the patient's primary point of contact. Key components include:

1. Referral and initial review: The referring physician sends medical records to the transplant centre. A transplant coordinator reviews them to confirm the referral is appropriate before scheduling.
2. Laboratory workup: Comprehensive blood and urine tests including complete metabolic panel, full blood count, coagulation profile, ABO blood typing, HLA tissue typing, panel reactive antibody (PRA) testing, viral serology (HIV, hepatitis B and C, CMV, EBV, VZV, HSV), tuberculosis screening (IGRA or Mantoux), RPR for syphilis, and cancer markers relevant to the organ being evaluated.
3. Imaging: Organ-specific imaging — ultrasound of the native kidneys or liver with Doppler assessment of vasculature, CT chest/abdomen/pelvis, echocardiogram, and nuclear stress testing or coronary angiography if cardiac risk factors are present.
4. Specialist consultations: Cardiology (mandatory for most organs), pulmonology, nephrology, hepatology, infectious disease, endocrinology (especially for diabetic patients), and gynaecology (for cervical cancer screening in female candidates).
5. Psychosocial evaluation: A transplant social worker and/or psychiatrist assesses mental health history, coping mechanisms, social support network, financial resources, insurance coverage, housing stability, and understanding of post-transplant obligations.
6. Transplant selection committee: All disciplines present their findings. The committee reaches a consensus decision: list, defer, or decline. The patient is notified and counselled on the outcome and any required next steps.
7. Education: Patients and caregivers receive education on post-transplant immunosuppression, infection prevention, dietary requirements, activity restrictions, and the importance of compliance.

A rigorous pre-transplant evaluation is directly associated with better post-transplant outcomes. Specific benefits include:

• Optimised organ matching: HLA typing and crossmatching reduce the risk of hyperacute rejection and improve long-term graft survival.
• Risk stratification and mitigation: Identifying and treating cardiovascular disease, infections, or malignancies before transplant prevents catastrophic post-operative complications.
• Improved survival rates: Kidney transplant recipients live on average 10–15 years longer than age-matched dialysis patients. Liver transplant five-year survival exceeds 75% at experienced centres.
• Quality-of-life restoration: Successful transplantation enables most patients to return to work, resume social activities, and discontinue dialysis or other burdensome treatments.
• Patient education: Understanding immunosuppression, rejection signs, and lifestyle requirements before transplant significantly improves medication adherence and self-management.
• Support system building: The social work evaluation identifies gaps in support, enabling early intervention and caregiver training.
• Appropriate resource allocation: Donor organs are a scarce resource. Careful evaluation ensures organs go to patients most likely to benefit, upholding the ethical principles of utility and equity.

While the evaluation itself carries minimal physical risk, the process involves several challenges that patients should be prepared for:

• Emotional burden: The evaluation can be stressful and emotionally taxing. Patients face uncertainty about the outcome and must confront their prognosis. Transplant centres offer counselling and peer support programs to help navigate this period.
• Risk of being declined or deferred: Not all patients who undergo evaluation are approved for listing. Receiving a 'deferred' or 'declined' recommendation is distressing, though in many cases deferral issues can be remedied.
• Invasive testing: Coronary angiography, liver biopsy, or cardiac catheterisation may carry their own procedural risks, particularly in patients who are already medically fragile.
• Waiting list uncertainty: Being listed does not guarantee receiving a transplant. Wait times vary enormously by organ, blood type, and region — from months to many years for some kidney candidates.
• Post-transplant risks identified during evaluation: The evaluation may reveal that the expected benefit is insufficient to justify the risks of surgery and lifelong immunosuppression, particularly in elderly or severely frail patients.
• Financial and logistical demands: Multiple appointments, travel to a specialist centre, time off work, and pre-transplant medical optimisation can impose significant burden on patients and families.

Transplant teams are experienced in supporting patients through these challenges, and early open communication between patient and team is strongly encouraged.

The post-evaluation period varies by the committee's decision:

• If listed (approved): The patient is registered on the national waiting list (e.g., UNOS/OPTN in the USA, NHS Blood and Transplant in the UK, NOTTO in India). Regular follow-up visits — typically every 3–6 months — are required to monitor disease progression, update the transplant team on any changes in medical status, and maintain transplant readiness. Patients who deteriorate significantly may be removed from the list if transplant is no longer safe.
• If deferred: A clear remediation plan is communicated. Common deferral reasons include the need for cardiac revascularisation, weight reduction to a target BMI, a defined period of sobriety, or cancer surveillance follow-up. Re-evaluation is scheduled once objectives are met.
• If declined: The team discusses the reasons in detail and, where possible, suggests alternative management strategies to optimise quality and length of life without transplantation. Patients may seek a second opinion at another transplant centre.

While awaiting transplant, patients must remain contactable 24 hours a day (organ offers can come at any time), maintain a packed hospital bag, avoid tobacco and alcohol, attend all follow-up appointments, report any infections or hospitalisations promptly, and continue to optimise their health and fitness.

Transplant evaluation costs vary widely by country, healthcare system, organ type, and individual complexity. Key cost components include:

• Specialist consultations: Fees for multiple specialist reviews (cardiology, pulmonology, infectious disease, psychiatry, nephrology/hepatology) — can total USD 2,000–8,000 in private settings.
• Laboratory investigations: Comprehensive blood panels, HLA typing, viral serology, and cancer markers typically cost USD 500–2,500.
• Imaging: CT scans, echocardiogram, nuclear stress tests, and Doppler ultrasound can add USD 1,000–5,000.
• Invasive procedures: Coronary angiography, liver biopsy, or cardiac catheterisation add USD 2,000–10,000.
• Psychosocial evaluation: Social work and psychiatric assessment fees, typically USD 300–1,000.
• Medical optimisation: Treatment of identified conditions (cardiac stenting, weight management programme, cancer treatment) before listing carries additional costs.

In countries with universal healthcare (UK, Canada, Australia), evaluation costs are largely covered by public funding. In the USA, Medicare covers transplant evaluation for eligible patients with ESRD. In India and other medical tourism destinations, evaluation packages may be offered at significantly lower cost — USD 1,500–5,000 all-inclusive — through accredited transplant centres. Patients should verify insurance coverage and pre-authorisation requirements before beginning evaluation.

Transplantation is not always possible or desirable. Alternatives depend on the organ involved and stage of disease:

• Kidney: Peritoneal dialysis and haemodialysis are life-sustaining alternatives that can maintain patients for years, though they carry significant lifestyle burdens and do not match the survival benefit of transplantation. Conservative kidney management (CKM) without dialysis is an evidence-based option for elderly or frail patients who may not benefit from renal replacement therapy.
• Liver: Transjugular intrahepatic portosystemic shunt (TIPS) for portal hypertension complications, endoscopic management of varices, ascites drainage, and hepatic encephalopathy management can extend quality of life. For selected hepatocellular carcinoma patients, locoregional therapies (TACE, ablation) or resection may be viable.
• Heart: Mechanical circulatory support — left ventricular assist devices (LVADs) — can serve as either a bridge to transplant or destination therapy for patients who are not transplant candidates. Optimal guideline-directed medical therapy and cardiac resynchronisation therapy are also important.
• Lung: Long-term oxygen therapy, pulmonary rehabilitation, and disease-modifying agents (e.g., antifibrotics for IPF) can slow progression. Endobronchial valve therapy is an option for selected emphysema patients.
• Pancreas: Continuous subcutaneous insulin infusion (insulin pump) with continuous glucose monitoring (CGM) and closed-loop artificial pancreas systems offer improved glycaemic control for Type 1 diabetics without the need for surgery.

The decision between transplantation and alternatives is highly personal and should be made collaboratively between patient, family, and the multidisciplinary transplant team, weighing expected survival benefit against quality of life and individual values.